Oral treatment of nintedanib for interstitial lung diseasesApril 4, 2020
Nintedanib oral capsules have been granted approval by the USFDA to treat patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.
The safety and effectiveness of nintedanib to treat chronic fibrosing ILD with a progressive phenotype in adults were evaluated in a randomized, double-blind, placebo-controlled study of 663 adults. The mean age of patients was 66 years and more patients were male (54%) than females.
The primary test for effectiveness was the forced vital capacity, which is a measure of lung function. It is defined as the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible.
In the 52-week period, patients received either 150 milligrams of nintedanib twice a day or a placebo. After 52 weeks, people who received nintedanib had less lung function decline compared to those on the placebo.